Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.45 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.45 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.45 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.45 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.45 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 8/20 | 0.44 |
| ▸ | HTR2C | P28335 | 3/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | AXL | P30530 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15031974 | 0.90 | MAPT (0.50) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL2862226 | 0.87 | L3MBTL1 (0.50) | SMN1; SMN2GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL1505362 | 0.87 | MAPT (0.52) | TSHRSMN1; SMN2MAPTNPSR1HTR2A | |
| SCHEMBL5859293 | 0.85 | TSHR (0.47) | TSHRSMN1; SMN2MAPTNPSR1TAAR1 | |
| SCHEMBL12957756 | 0.85 | NQO2 (0.48) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL17807469 | 0.84 | AXL (0.46) | TSHRSMN1; SMN2GRIN2DGRIN3BGRIN1 | |
| SCHEMBL1104878 | 0.84 | GRIN2D (0.52) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL28799442 | 0.81 | POLB (0.61) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL680329 | 0.81 | POLB (0.61) | TSHRGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL298224 | 0.81 | POLB (0.59) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109053391-B | Micro-reaction system and method for synthesizing 4-bromo-3-methylanisole by two-phase method | 山东道可化学有限公司 | 2022-06-28 | — | — | CN | disclosed |
| US-9373792-B2 | Anthracene derivative and organic electroluminescent element using the same | IDEMITSU KOSAN CO., LTD. (JP) | 2016-06-21 | — | — | US | disclosed |
| US-20150372237-A1 | ANTHRACENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT USING THE SAME | IDEMITSU KOSAN CO., LTD (JP) | 2015-12-24 | — | — | US | disclosed |
| US-9147847-B2 | Anthracene derivative and organic electroluminescent element using the same | IDEMITSU KOSAN CO., LTD. (JP) | 2015-09-29 | — | — | US | disclosed |
| US-20150005512-A1 | ANTHRACENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT USING THE SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2015-01-01 | — | — | US | disclosed |
| US-8866135-B2 | Anthracene derivative and organic electroluminescent element using the same | IDEMITSU KOSAN CO., LTD. (JP) | 2014-10-21 | — | — | US | disclosed |
| US-8796459-B2 | Process and intermediates for preparing integrase inhibitors | GILEAD SCIENCES, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-8759525-B2 | Process and intermediates for preparing integrase inhibitors | Gilhead Sciences, Inc. (US) | 2014-06-24 | — | — | US | disclosed |
| US-20140159005-A1 | ANTHRACENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT USING THE SAME | IIDEMITSU KOSAN CO., LTD (JP) | 2014-06-12 | — | — | US | disclosed |
| US-8629430-B2 | Anthracene derivative and organic electroluminescent element using the same | IDEMITSU KOSAN CO., LTD. (JP) | 2014-01-14 | — | — | US | disclosed |
| US-20130253200-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-8440831-B2 | Process and intermediates for preparing integrase inhibitors | GILEAD SCIENCES, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-20130116437-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-8324244-B2 | Process and intermediates for preparing integrase inhibitors | GILEAD SCIENCES, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20120238758-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| US-20120138914-A1 | ANTHRACENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT USING THE SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2012-06-07 | — | — | US | disclosed |
| US-20110160458-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140159005-A1 | ANTHRACENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT USING THE SAME | SOX18, ANXA1, ANXA11 | TSHR 2608/4885SMN1; SMN2 2656/4885GRIN2D 3628/4885 |
| US-20120238758-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | TYMS, TYMP, POLB | TSHR 4554/4885SMN1; SMN2 3321/4885GRIN2D 3604/4885 |
| US-20150372237-A1 | ANTHRACENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT USING THE SAME | SOX18, ANXA1, ANXA11 | TSHR 2608/4885SMN1; SMN2 2656/4885GRIN2D 3628/4885 |
| US-20120138914-A1 | ANTHRACENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT USING THE SAME | SOX18, ANXA1, ANXA11 | TSHR 2608/4885SMN1; SMN2 2656/4885GRIN2D 3628/4885 |
| US-20130116437-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | TYMS, TYMP, POLB | TSHR 4554/4885SMN1; SMN2 3321/4885GRIN2D 3604/4885 |
| US-20150005512-A1 | ANTHRACENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT USING THE SAME | SOX18, ANXA1, ANXA11 | TSHR 2608/4885SMN1; SMN2 2656/4885GRIN2D 3628/4885 |
| US-20110160458-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | TYMS, TYMP, POLB | TSHR 4554/4885SMN1; SMN2 3321/4885GRIN2D 3604/4885 |
| US-20130253200-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS | TYMS, TYMP, POLB | TSHR 4554/4885SMN1; SMN2 3321/4885GRIN2D 3604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.